Eqis Capital Management Inc. raised its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,967 shares of the company’s stock after buying an additional 1,246 shares during the period. Eqis Capital Management Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $364,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in TEVA. Schulhoff & Co. Inc. raised its stake in Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares in the last quarter. Heritage Investors Management Corp raised its stake in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares in the last quarter. Bank Hapoalim BM raised its stake in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares in the last quarter. M Holdings Securities Inc. purchased a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter worth about $491,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock worth $165,461,000 after buying an additional 801,106 shares in the last quarter. 56.04% of the stock is currently owned by institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 1.17% during trading on Friday, reaching $17.30. The company’s stock had a trading volume of 9,162,890 shares. The stock has a 50-day moving average of $27.46 and a 200-day moving average of $30.98. The stock’s market cap is $17.58 billion. Teva Pharmaceutical Industries Limited has a 52-week low of $16.81 and a 52-week high of $53.96.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s revenue was up 12.9% compared to the same quarter last year. During the same period last year, the business posted $1.25 earnings per share. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -18.95%.

ILLEGAL ACTIVITY WARNING: “Eqis Capital Management Inc. Increases Stake in Teva Pharmaceutical Industries Limited (TEVA)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/19/teva-pharmaceutical-industries-limited-teva-stake-boosted-by-eqis-capital-management-inc-updated-updated-updated.html.

A number of equities research analysts recently issued reports on the company. BidaskClub lowered Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Citigroup Inc. lowered Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and dropped their target price for the company from $32.00 to $19.00 in a research report on Wednesday. Zacks Investment Research lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price target (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $26.00 price target (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, twenty have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and a consensus price target of $36.73.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.